Here's some math from the PR for everyone to think
Post# of 72447
(Total Views: 513)
Posted On: 05/09/2018 6:52:45 PM
Here's some math from the PR for everyone to think about:
65,000 cases each year in US of OM of only the head and neck cancers @ $18,000-$25,000 in resulting extra hospital costs. Likely tens of thousands of more cases with all the other cancers included.
If B is used on half those H&N cancer patients and is priced modestly at $2,000 per treatment , then we are talking $65M in revenue (not including if there are needs for multiple treatments).
Now take the 750,000 cases world wide. Say B is used in 15% of those at $2,000 per treatment, now we are talking $250M in revenue each year.
So if B is capable of pulling in $315M a year in revenue, and my numbers are likely VERY modest, you have a potential of a $2.2B revenue stream for this indication over a 7 year patent. Anybody have an opinion on what a partner will be willing to pay for a drug capable of pulling in a $315M a year? I dont, so it is an honest question.
I dont pretend to know if $2,000 a treatment is high or low either, but if one can potentially save a patient and/or insurance provider $16,000+ by using it, I imagine that no one will blink an eye at $2,000. Most likely a B-OM treatment will command a higher cost.
Lets debate this instead of bashers and stock board trolls.
65,000 cases each year in US of OM of only the head and neck cancers @ $18,000-$25,000 in resulting extra hospital costs. Likely tens of thousands of more cases with all the other cancers included.
If B is used on half those H&N cancer patients and is priced modestly at $2,000 per treatment , then we are talking $65M in revenue (not including if there are needs for multiple treatments).
Now take the 750,000 cases world wide. Say B is used in 15% of those at $2,000 per treatment, now we are talking $250M in revenue each year.
So if B is capable of pulling in $315M a year in revenue, and my numbers are likely VERY modest, you have a potential of a $2.2B revenue stream for this indication over a 7 year patent. Anybody have an opinion on what a partner will be willing to pay for a drug capable of pulling in a $315M a year? I dont, so it is an honest question.
I dont pretend to know if $2,000 a treatment is high or low either, but if one can potentially save a patient and/or insurance provider $16,000+ by using it, I imagine that no one will blink an eye at $2,000. Most likely a B-OM treatment will command a higher cost.
Lets debate this instead of bashers and stock board trolls.
(7)
(0)